These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27532222)

  • 21. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
    Schmid S; Siano M; Joerger M; Rodriguez R; Müller J; Früh M
    Lung Cancer; 2015 Jan; 87(1):85-7. PubMed ID: 25466451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
    Nehs MA; Nucera C; Nagarkatti SS; Sadow PM; Morales-Garcia D; Hodin RA; Parangi S
    Endocrinology; 2012 Feb; 153(2):985-94. PubMed ID: 22202162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
    Sharman JP; Chmielecki J; Morosini D; Palmer GA; Ross JS; Stephens PJ; Stafl J; Miller VA; Ali SM
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e161-3. PubMed ID: 24997557
    [No Abstract]   [Full Text] [Related]  

  • 26. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
    Takano T; Ito Y; Hirokawa M; Yoshida H; Miyauchi A
    Br J Cancer; 2007 May; 96(10):1549-53. PubMed ID: 17453004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.
    Aylwin SJ; Bodi I; Beaney R
    Pituitary; 2016 Oct; 19(5):544-6. PubMed ID: 26115708
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
    Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
    JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
    [No Abstract]   [Full Text] [Related]  

  • 29. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
    Charles J; Beani JC; Fiandrino G; Busser B
    J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
    [No Abstract]   [Full Text] [Related]  

  • 30. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
    Husain A; Hu N; Sadow PM; Nucera C
    Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
    Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
    J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
    [No Abstract]   [Full Text] [Related]  

  • 32. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
    Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
    Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
    [No Abstract]   [Full Text] [Related]  

  • 33. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
    Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma Drug Works in Other Tumors.
    Cancer Discov; 2015 Nov; 5(11):1117. PubMed ID: 26385779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follicular variant of papillary thyroid carcinoma with B-type Raf(V600E) showing higher frequency of suspicious sonographic features and multifocality.
    Shin DY; Kim KJ; Chang S; Kim H; Hwang S; Kim W; Bae J; Park S; Kang SW; Chung WY; Lee EJ
    Head Neck; 2015 Nov; 37(11):1590-5. PubMed ID: 24909403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
    Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
    J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.